Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series B
Biotech
Marrow extracts $120M series B for blood disease drug
Marrow Therapeutics’ in vivo drug candidate targets sickle cell disease and beta thalassemia with buy-in from healthcare investment giant OrbiMed.
Michael Gibney
Nov 17, 2026 7:00am
Addex spinout raises $105M series B for schizophrenia ph. 2
Nov 12, 2026 3:56am
T-Therapeutics raises $133M series B with Big Pharma backers
Nov 5, 2026 4:00am
Matchpoint nets $150M series B to take covalent med into clinic
Oct 7, 2026 8:15am
Pfizer vet debuts Khartis with sights set on thyroid eye disease
Aug 13, 2026 9:00am
Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
Aug 11, 2026 7:00am